Table 5. Characteristics of breast cancer patients under study group.
| Charateristics | n (%) | |
|---|---|---|
| GENERAL | Age at diagnosis (years) | |
| • ≤39 | 26 (8.0) | |
| • 40-50 | 222 (68.5) | |
| • ≥61 | 76 (23.5) | |
| Mean age at diagnosis in years (min-max) | 54.7 (22.4-79.0) | |
| Year of diagnosis | ||
| • 1997-2004 | 15 (4.6) | |
| • 2005-2009 | 289 (89.2) | |
| • 2010-2012 | 20 (6.2) | |
| Histopathology | ||
| • invasive ductal carcinoma | 230 (71.1) | |
| • invasive lobular carcinoma | 22 (6.8) | |
| • carcinoma mixed type | 6 (1.8) | |
| • other | 29 (8.9) | |
| • unspecified | 37 (11.4) | |
| Tumor grade | ||
| • G1 | 39 (12.0) | |
| • G2 | 71 (21.9) | |
| • G3 | 83 (25.8) | |
| • Bloom I | 5 (1.5) | |
| • Bloom II | 12 (3.7) | |
| • Bloom III | 12 (3.7) | |
| • unspecified | 102 (31.4) | |
| RECEPTORS | Estrogen receptor status | |
| • negative | 115 (35.5) | |
| • positive | 190 (58.6) | |
| • unspecified | 19 (5.9) | |
| Progesterone receptor status | ||
| • negative | 133 (41.0) | |
| • positive | 172 (53.1) | |
| • unspecified | 19 (5.9) | |
| HER2 status | ||
| • negative | 103 (31.8) | |
| • positive | 167 (61.5) | |
| • unspecified | 54 (16.7) | |
| triple-negative breast cancer (TNBC) | 37 (11.4) | |
| TNM staging | Tumor (T) | |
| • 0 | 2 (0.6) | |
| • 1 | 43 (13.3) | |
| • 2 | 97 (29.9) | |
| • 3 | 52 (16.0) | |
| • 4 | 82 (25.3) | |
| • unspecified | 50 (15.5) | |
| Nodes (N) | ||
| • 0 | 85 (26.2) | |
| • 1 | 108 (33.3) | |
| • 2 | 67 (20.7) | |
| • 3 | 19 (5.8) | |
| • 4 | 1 (0.3) | |
| • inspecified | 44 (13.6) | |
| Metastases (M) | ||
| • 0 | 258 (79.6) | |
| • 1 | 25 (7.7) | |
| • unspecified | 42 (12.7) | |
| Metastases locations | ||
| • liver | 8 (32.0) | |
| • lungs | 3 (12.0) | |
| • bones and lungs | 3 (12.0) | |
| • bones | 2 (8.0) | |
| • other | 9 (36.0) | |
| THERAPY | Surgery | |
| • amputation | 187 (57.7) | |
| • conserving surgery. including: | 87 (26.8) | |
| • with radicalization | 14 (4.3) | |
| • without radicalization | 73 (22.5) | |
| • none | 50 (15.5) | |
| Hormonotherapy | ||
| • yes | 204 (63.0) | |
| • no | 120 (37.0) | |
| Immunotherapy (Herceptine) | ||
| • yes | 36 (11.1) | |
| • no | 288 (88.9) | |
| Chemotherapy FAC | ||
| • adjuvant | 136 (42.0) | |
| • neoadjuvant | 188 (58.0) | |
| mean numer of cycles (range) | 6.1 (3-9) | |
| Radiotherapy | ||
| • yes | 265 (81.8) | |
| • no | 59 (18.2) | |
| • brachytherapy | 7 (2.2) | |
| mean radiation dose in Gy (range) | 50.2 (20-70) | |
| mean radiation dose in brachytherapy (range) | 14 (10-30) | |
| FOLLOW-UP | Deaths | |
| • yes | 85 (26.2) | |
| • no | 239 (73.8) | |
| median OS in months (min-max) | 57.6 (4.3-156.2) | |
| Progression | ||
| • yes | 99 (30.6) | |
| • no | 225 (69.4) | |
| median PFS in months (min-max) | 54.1 (0.9-152.1) | |
| Progression- locations of metastases | ||
| • bones | 28 (28.3) | |
| • multiorgan spread | 27 (27.3) | |
| • lungs | 8 (8.1) | |
| • liver | 8 (8.1) | |
| • lymph nodes | 8 (8.1) | |
| • tumor growth | 8 (8.1) | |
| • central nervous system | 7 (7.1) | |
| • skin | 4 (4.0) | |
| • eye socket | 1 (1.0) | |
| Recurrence | ||
| • yes | 12 (3.7) | |
| • no | 312 (96.3) | |
| median RFS in months (min-max) | 55.0 (0.5-152.1) | |
| Metachronous primary breast cancer | ||
| • yes | 8 (2.5) | |
| • no | 316 (97.5) | |
| median survival to next breast cancer diagnosis in months (min-max) | 55.0 (0.5-152.1) |
HER2- human epidermal growth factor receptor-2; PFS- progression-free survival; RFS- recurrence-free survival